Eisai Thailand and BKGI Join Forces to Transform Alzheimer’s Care: Innovative Blood-Testing Technology Brings New Hope for Early Detection and Treatment

Bangkok (January 9, 2024) – Eisai (Thailand) Marketing Co., Ltd., a leader in Alzheimer’s disease and neurological disorder treatment development, has partnered with Bangkok Genomics Innovation Public Company Limited (BKGI), Thailand’s leader in genetic analysis and biomarker innovation. The companies signed a Memorandum of Understanding (MOU) to enhance Alzheimer’s disease screening and treatment, aiming to develop a comprehensive ecosystem for Alzheimer’s patient care in Thailand. The signing ceremony was held at Renaissance Bangkok Ratchaprasong Hotel.

This collaboration marks the first time in Thailand that a leading Alzheimer’s treatment pharmaceutical company and a Thai leader in genetic analysis and biomarker innovation have joined forces to combine their organizational strengths, offering comprehensive solutions including:

  • Initial screening through CogMate™, an online platform for self-assessment of brain health
  • Blood-based and cerebrospinal fluid testing for disease-causing proteins including Amyloid Beta and p-Tau217 for accurate screening and diagnosis
  • Genetic analysis of Alzheimer’s disease-related genes
  • Comprehensive personalized genetic risk assessment innovation

These innovations will help those concerned about Alzheimer’s disease evaluate and understand their risk factors early. Test results can be used to plan risk reduction strategies and enhance holistic preventive factors to avoid Mild Cognitive Impairment (MCI) and Alzheimer’s disease. Furthermore, this collaboration will help patients or those at risk of Alzheimer’s disease, or those with mild memory impairment without symptoms, access screening, diagnosis, and treatment from the early stages, resulting in increased chances of successful treatment.

Mr. Nattapan Nimmanpatcharin, Managing Director of Eisai (Thailand) Marketing Co., Ltd., stated:
“This significant collaboration between Eisai and BKGI marks an important step in elevating care for patients with Mild Cognitive Impairment (MCI) and Alzheimer’s disease in Thailand. Currently, Eisai has innovative self-assessment brain health screening (CogMate™) and new innovative medicines that have been approved in many countries and will soon be approved for use in Thailand. Therefore, screening technology is crucial for confirmation before entering treatment with new innovative medicines. Accurate blood-based biomarker testing for disease-indicating proteins such as beta-amyloid or tau protein (Serum Blood-based biomarker), cerebrospinal fluid testing (CSF), and genetic analysis for this disease are extremely important to ensure that patients will have the opportunity to respond to and succeed with this new innovative treatment. Strengthening our partnership with BKGI will help patients access blood-based biomarker confirmation testing and genetic testing quickly at accessible prices. Screening and diagnosis of patients and those at risk, especially those with memory impairment issues from the pre-symptomatic stage, at age 50 and above will increase the chances of successful early treatment. Eisai hopes this collaboration will be the beginning of creating positive changes for Alzheimer’s patients and their families in Thailand.”

Professor Dr. Thosaporn Sirisumphand, Chairman of Bangkok Genomics Innovation Public Company Limited (BKGI), stated:
“Early detection of Alzheimer’s disease is a crucial factor in improving treatment efficiency. Similar to cancer, starting Alzheimer’s treatment early can significantly slow disease progression and improve patients’ quality of life, especially when using highly effective medications that need to be administered while symptoms are still mild. The collaboration between BKGI and Eisai Thailand has brought advanced technology that can accurately detect disease-causing proteins from blood. This technology offers a new alternative that reduces limitations of traditional testing methods and enhances the capability to diagnose Alzheimer’s disease in its early stages. When combined with effective innovative medicines, these advancements will be a significant step in transforming treatment approaches. Enhancing screening capabilities, developing disease-causing protein detection, and proactive treatment will help elevate early-stage diagnosis and patient care. These efforts play a crucial role in reducing the social and economic impact of neurodegenerative diseases in Thailand and worldwide.”

This collaboration not only establishes a business partnership but also reflects a commitment to creating a better future for patients, families, and Thai society. It represents a significant step in making Alzheimer’s disease no longer an unsolvable problem. The goal is to make this disease manageable, enabling everyone to have a better and sustainable quality of life.

This innovation represents new hope for Alzheimer’s patients in Thailand and reflects the advancement of technology that plays a crucial role in elevating healthcare in an aging society.

The collaboration will combine the strengths of both organizations, with BKGI bringing expertise in Alzheimer’s-specific protein level testing through blood tests and genetic testing, integrated with Eisai’s self-assessment brain health innovation and new innovative medicines, to develop a comprehensive brain health care system from prevention and screening to accurate diagnosis, leading to appropriate and timely treatment.

go to top